Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

News Center

6756758(2)-91.jpg

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development

Learn More

All

2025

2024

2023

2022

2021

2020

LaNova Medicines Announces IND Approval of LM-317 by US FDA

2024-06-10

Learn More
LaNova Medicines Initiates First Phase III Clinical Trial for LM-302 in China

2024-04-11

Learn More
FDA Granted LM-108 Orphan Drug Designations for Cancer Treatments

2023-12-18

Learn More
CDE Granted LM-302 Breakthrough Therapy Designation for Claudin 18.2 positive GC/GEJ

2023-11-23

Learn More
LaNova Medicines Announces IND Approval of LM-24C5 by US FDA

2023-09-28

Learn More
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate

12 May, 2023, LaNova Medicines announced today it has entered into an exclusive license agreement with AstraZeneca for anti-GPRC5D ADC LM-305

2023-05-12

Learn More

3